AngioDynamics Corp (ANGO) - Multiplikator forward rega marang pendapatan
Global supply risks and export barriers are driving volatility, which is evident in the forward P/S valuation of AngioDynamics, Inc. (ANGO), where 1.60 captures the current value of the indicator. Growth is based on the implementation of profitable systems for oncology and vascular surgery. Simultaneously, the business relies on organic development, divesting loss-making assets to optimize its structure.
AngioDynamics Inc. - rincian analitis lan metrik utama (ANGO)
- rega pasar lan target rega analis:
- indikator kapitalisasi pasar:
- rincian valuasi buku bisnis:
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas AngioDynamics, Inc.|ANGO - Rasio utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas AngioDynamics, Inc.|ANGO - Tanggungan utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku AngioDynamics Inc.|ANGO - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan AngioDynamics|Likuiditas cepet angiodynamics.com
- data bathi bisnis lan rasio investasi:
ANGO - Bathi perusahaan|Proyeksi bathi mangsa ngarep AngioDynamics, Inc.|ANGO - Rasio kapitalisasi marang bathi resik|Pangali Forward P/E AngioDynamics Corp|ANGO - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan AngioDynamics Inc.|ANGO - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) AngioDynamics|ANGO - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan angiodynamics.com|ANGO - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep AngioDynamics, Inc.
- data dodolan lan asil:
Analisis umum perusahaan:ANGO (AngioDynamics)
The patent-protected minimally invasive surgery segment and stringent FDA requirements create a sustainable barrier to entry for AngioDynamics, Inc. (ANGO), minimizing competitive risks. An analysis of the forward price-to-sales ratio allows for an assessment of the company's market value relative to expected sales, revealing hidden business vulnerabilities and determining the extent to which current capitalization is justified by expansion rates amid rising operating expenses.
Analisis perusahaan pesaing
Rasio rega marang prakiraan pendapatan Intuitive ISRG|Rega forward marang dodolan DHR|BDX: Multiplikator forward rega marang pendapatan|STE - Multiplikator Forward P/S|West Pharmaceutical Services (WST) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan baxter.com|MASI (Masimo) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Stevanato Group SpA STVN|Rasio rega marang prakiraan pendapatan Teleflex Inc (TFX)|Merit Medical Corp - Kapitalisasi marang prakiraan pendapatan|Envista Holdings - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake ICUI (icumed.com)|XRAY - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake LeMaitre Vascular Inc LMAT|ATRC: Multiplikator Forward P/S|STAAR Surgical Co (STAA) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan ChromaDex Corporation|Kapitalisasi marang prakiraan pendapatan ZIMV (zimvie.com)|Multiplikator Forward P/S CERS|Alpha Teknova (TKNO) - Prakiraan rega marang pendapatan|Multiplikator Forward P/S MGRM (Monogram Technologies Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Sharps Technology Inc (STSS)|INFU - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep utahmed.com|KRMD: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan NYXH|Multiplikator forward rega marang pendapatan MBOT|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pro-Dex Inc. PDEX|Rasio rega marang prakiraan pendapatan Zentek Ltd. (ZTEK)|elutia.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S MLSS (Milestone Scientific Inc.)|Multiplikator Forward P/S NEXGEL Inc. NXGL|RVP - Rasio rega marang prakiraan pendapatan|harvardbioscience.com (HBIO) - Multiplikator forward rega marang pendapatan|FEMY: Multiplikator Forward P/S|MHUA - Rasio kapitalisasi marang dodolan sing dikarepake|POAI (Predictive Oncology Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Callan JMB Corp (CJMB)|Rasio rega marang prakiraan pendapatan Atrion Corp (ATRI)|Rasio kapitalisasi marang dodolan sing dikarepake NeuroMetrix Corporation
